会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • MIRNA BASED TREATMENT MONITORING IN MULTIPLE SCLEROSIS
    • MIRNA治疗多发性硬化的疗效观察
    • WO2013131567A1
    • 2013-09-12
    • PCT/EP2012/053944
    • 2012-03-07
    • FEBIT HOLDING GMBHKELLER, AndreasBEIER, MarkusSCHEFFLER, MatthiasWENDSCHLAG, AnkeAKTAS, OrhanINGWERSEN, JensHARTUNG, Hans-PeterKÜRY, PatrickPROZOROVSKI, Timour
    • KELLER, AndreasBEIER, MarkusSCHEFFLER, MatthiasWENDSCHLAG, AnkeAKTAS, OrhanINGWERSEN, JensHARTUNG, Hans-PeterKÜRY, PatrickPROZOROVSKI, Timour
    • C12Q1/68
    • C12Q1/6883C07K16/2842C12Q2600/106C12Q2600/118C12Q2600/136C12Q2600/158C12Q2600/178
    • The present invention relates to methods of determining whether a patient responds to a therapeutic treatment of multiple sclerosis (MS), of monitoring the course of multiple sclerosis (MS) in a patient, of determining the risk for a relapse of multiple sclerosis (MS) in a patient, and of adjusting the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient. Said methods are based on the determination of the level of at least one miRNA in a test sample isolated from the patient. The present invention also relates to a method of identifying a compound suitable for the treatment of multiple sclerosis in a patient. Further, the present invention relates to the use of a polynucleotide or a polynucleotide set for detecting a miRNA to determine whether a patient responds to a therapeutic treatment of multiple sclerosis, to monitor the course of multiple sclerosis in a patient, to determine the risk of a relapse of multiple sclerosis in a patient, to adjust the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient, and to identify a compound suitable for the treatment of multiple sclerosis in a patient. Furthermore, the present invention relates to a kit for determining whether a patient responds to a therapeutic treatment of multiple sclerosis, for monitoring the course of multiple sclerosis in a patient, for determining the risk of a relapse of multiple sclerosis in a patient, for adjusting the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient, or for identifying a compound suitable for the treatment of multiple sclerosis in a patient comprising means for determining the level of at least one miRNA in a test sample isolated from a patient.
    • 本发明涉及确定患者是否对多发性硬化症(MS)的治疗性处理作出反应,监测患者中多发性硬化症(MS)的过程,确定患者 患者中多发性硬化症(MS)的复发以及调整应用于患者中多发性硬化症的治疗性治疗的治疗药物的剂量。 所述方法基于确定从患者分离的测试样品中的至少一种miRNA的水平。 本发明还涉及鉴定适合于治疗患者多发性硬化症的化合物的方法。 此外,本发明涉及用于检测miRNA的多核苷酸或多聚核苷酸的用途,以确定患者是否对多发性硬化症的治疗性处理作出反应,监测患者中多发性硬化的进程,以确定 患者中多发性硬化症的复发,调整应用于患者中多发性硬化症的治疗性治疗的治疗药物的剂量,以及鉴定适合于治疗患者中多发性硬化症的化合物。 此外,本发明涉及用于确定患者是否对多发性硬化症的治疗性处理作出反应,用于监测患者中多发性硬化症的过程,用于确定患者中多发性硬化症复发的风险的试剂盒,用于调整 用于治疗性治疗患者中多发性硬化症的治疗药物的剂量,或用于鉴定适合于治疗患者中多发性硬化症的化合物的剂量,所述方法包括用于确定从患者的多发性硬化症分离的测试样品中的至少一种miRNA的水平的工具 患者
    • 8. 发明申请
    • MIRNA BASED TREATMENT MONITORING IN AUTOIMMUNE DISEASES
    • 自发性疾病基于MIRNA的治疗监测
    • WO2015032789A1
    • 2015-03-12
    • PCT/EP2014/068668
    • 2014-09-03
    • COMPREHENSIVE BIOMARKER CENTER GMBHBEIER, MarkusSCHEFFLER, MatthiasAKTAS, OrhanINGWERSEN, Jens
    • BEIER, MarkusSCHEFFLER, MatthiasAKTAS, OrhanINGWERSEN, Jens
    • C12Q1/68
    • C12Q1/6883C12Q2600/106C12Q2600/118C12Q2600/158C12Q2600/178
    • The invention relates to methods of determining whether a patient responds to a therapeutic treatment of an autoimmune disease, of monitoring the course of an autoimmune disease in a patient, of determining the risk for a relapse of an autoimmune disease in a patient, and of adjusting the dose of a therapeutic drug applied for therapeutic treatment of an autoimmune disease in a patient. Said methods are based on the determination of the level of at least one miRNA in a test sample isolated from the patient. The invention also relates to a method of identifying a compound suitable for the treatment of an autoimmune disease in a patient. Further, the invention relates to the use of a polynucleotide or a polynucleotide set for detecting a miRNA to determine whether a patient responds to a therapeutic treatment of an autoimmune disease, to monitor the course of an autoimmune disease in a patient, to determine the risk of a relapse of an autoimmune disease in a patient, to adjust the dose of a therapeutic drug applied for therapeutic treatment of an autoimmune disease in a patient, and to identify a compound suitable for the treatment of an autoimmune disease in a patient. Furthermore, the invention relates to a kit for determining whether a patient responds to a therapeutic treatment of an autoimmune disease, for monitoring the course of an autoimmune disease in a patient, for determining the risk of a relapse of an autoimmune disease in a patient, for adjusting the dose of a therapeutic drug applied for therapeutic treatment of an autoimmune disease in a patient, or for identifying a compound suitable for the treatment of an autoimmune disease in a patient comprising means for determining the level of at least one miRNA in a test sample isolated from a patient. Said autoimmune disease is not multiple sclerosis (MS).
    • 本发明涉及确定患者对自身免疫性疾病的治疗性治疗,监测患者自身免疫性疾病进程的响应,确定患者自身免疫疾病复发风险的方法以及调整 用于治疗患者自身免疫疾病的治疗药物的剂量。 所述方法基于从患者分离的测试样品中至少一种miRNA的水平的确定。 本发明还涉及鉴定适合于治疗患者自身免疫性疾病的化合物的方法。 此外,本发明涉及多核苷酸或多核苷酸组用于检测miRNA以确定患者是否对自身免疫疾病的治疗性治疗作出反应,以监测患者自身免疫疾病的过程以确定风险的用途 患者自身免疫性疾病的复发,调整用于患者自身免疫性疾病治疗性治疗的治疗药物的剂量,以及鉴定适合于治疗患者自身免疫疾病的化合物。 此外,本发明涉及一种用于确定患者是否对自身免疫性疾病的治疗性治疗作出反应以用于监测患者自身免疫性疾病的过程以确定患者自身免疫性疾病的风险的试剂盒, 用于调节用于治疗性治疗患者自身免疫疾病的治疗药物的剂量,或用于鉴定适合于治疗患者自身免疫性疾病的化合物,其包括测定试验中至少一种miRNA水平的方法 从患者分离的样品。 所述自身免疫性疾病不是多发性硬化症(MS)。